TIFFANY NIXON: Open Payments
NPI 1447888474 · DUNKIRK, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$643 in 38 payments from 10 companies in 2025. Trend: 2023 $530 · 2024 $353 · 2025 $643
Food & beverage: $643
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $216 |
| AstraZeneca Pharmaceuticals LP | 11 | $174 |
| PFIZER INC. | 4 | $69 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $59 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Novo Nordisk Inc | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $15 |
| Exact Sciences Corporation | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
Products named: VRAYLAR, FARXIGA, QULIPTA, AIRSUPRA, ELIQUIS, JARDIANCE, Auvelity, Wegovy.
Industry payments across IN — which companies pay providers there.
